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\. EXPLANATORY MEMORANDUM 
In  recent  decades,  medicine  and  medical  research  have· made  remarkable  progress  in 
saving lives, extending life expectancy and ridding the world of  a number of  diseases.  The 
most spectacular successes of all  have been in  the use of vaccines to prevent childhood 
illnesses, in the use of antibiotics to combat infectious diseases and in the development of 
anti-viral medicinal products for the diagnosis,  prevention or treatment of AIDS.  ·Great 
strides  have  also  been  made  in  the  diagnosis,  prevention  or treatment  of cancer  and 
cardiovascular diseases.  .  · 
Nevertheless, there are still  a great' many diseases which cannot be treated satisfactorily 
and for which no medication or other diagnosis, prevention or treatment is  available.  In 
addition to the widespread  and  well-known diseases of this  kind,  there is  also  a whole 
series of diseases which affect relatively few  people; approximately 5 000 such  diseases 
have  been  identified.  The -pharmaceutical  industry  is  reluctant· to  develop  medicinal 
,  products  to  treat  these  diseases:  pharmaceutical  research  and  development  are  so 
. expensive nowadays that there is practically no  chance of any company making the effort 
to develop a medicinal product, to obtain authorisation for its use and to place it  on the 
market if it  is to be  supplied at normal prices to_ the few patients who require it.  That is 
why such medicinal products are known as "orphan medidnar products". 
Society cannot accept that certain individuals be denied the benefits of medical  progress 
.simply because the affliction from which they suffer affects only a small number of  people. 
It is therefore up to the public authorities to provide the necessary incentives and to adapt 
their:  administrative  procedures  so  as  to  make  it  as  easy  as  possible  to  provide these 
patients  with  medicinal ·products  which  are  just' as  safe  and- effective  as  any  other 
medicinal product and meet the same quality standards. 
In  the  Unite~ States,  an  incentive  system  for  the  development  of orphan  medicinal 
products  (the  "Orphan  Drug  Act")  was  introduced  iri  1983.  All  designated  orphari 
products  are  eligible  for  a  federal  tax  credit  equal  to ·50  %  of the .clinical  research 
,expenditure;  orphan  products are exempted from  the application fee  for  FDA approval, 
and  the  first  product  authorised  for  a  specific  indication  gets  a  seven-year  marketing 
exclusivity period. Congress also appropriates around $ 20 mittion for FDA for-grants for 
orphan products.  Over. the last  13  years 83 7 medicinal  products have been awarded. the 
status of  orphan drug, of  which 323 have been aic;led \Jy. the grants program. At  the end of 
1997,  152 orphan products had gone on to obtain marketing approval and are now being 
used by over  _7  million patients.  ·  · 
The success of the U.S.· orphan drug program has stimulated many foreign  countries to 
.seek to emulate it.  A similar regime was introduced in Japan in  1995, in Singapore in  1997 
and in Australia in  1998. 
In the European Union, in the course of  the last decade, a number of Member States have 
adopted,specific measures to increase our knowledge of  rare diseases and to improve their 
detection, diagnosis,  prevention or treatment.  In  some cases, the relevant legislation or 
administrative  provisions  include  a 'reference  to  the  concept  of "orphan .  drug"  or 
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"uneconomic  drug".  These ·initiatives,  however,  are  few  and  far  between  and  have · 
certainly not led toany significant progress in research on rare diseases  . 
. At  Community level,  the fourth  Framework Programme for  research and  technological 
development  (1994-98),  and  in  particular  the_  "Biomeclicine  and  Health"- programme 
(Biomed 2),  covers  research  on  the  development  of orphan  mediCinal  and  supports 
fundamental, clinical and  ~pidemiological research on rare diseases.  .  . 
Rare diseases have further been identified as a priority area for Community action within 
the framework for action in the field  of public health (COM(93) 559 final  and COM(97) 
225 final).  The Commission has recently proposed a Decision of  the European Parliament 
and  Council  adopting a  programme of Community  action· 1999-2003  on rare  diseases, 
including  a~tions to provide  information,  to  deal  with  cluster~ of rare  diseases  in  a.  · 
population and to support relevant patient organisations. · 
Experience  in  the  U~ited States  and  Japan  clearly  shows  tha~ the key. elt~ment in  an 
effective policy ofsupport for orphan medicinal products research and development isthe 
creation  of an  officiar system  for  recognising  orphan  medicinal  products  and  granting 
exclusiv~ marketing rights for a sufficient period of  time froin the date·  ~hen  the medicinal-
. product is actually placed on ~he market.  ·  '  ·  · 
JUSTIFICATION 
Objective 
The aim  of this proposal is  to establish a Community procedure for designating orphan 
medicinal  products and to introduce incentives for orphan, medicinal  products research, 
development and marketing, ·in particular by granting exclusive marketing·rights for a ten· 
year period.  ·  · 
This  p~oposal falls  within  a'  context  of ~he completion  of the  internal  market  and  is· 
featur~d in the Com_mission's work programme for '1997. 
LegaLbasis and procedure 
The·pr_oposaL,establishes harmonised criteria and a Community procedure for designating 
orphan  medicinal  products;  it: provides  access  to  the  Community  ma(ket,  via  the·· 
··centralised  authoris~tion  procedure,  for  the ·medicinal  products  thus .. designated -and 
confers upon them ex;clusive  marketing rights throughout the Community for a· ten year 
period. 
.  I 
Article. 1  OOa  of the EC Treaty constitutes the appropriate legal  basis for such a scheme.. 
The importance of  the 'market exclusivity' provision as an incentive to the success· of  this 
. m_easure  has .been· reinforced  by  the  experience ~in  the  United  States ·and  Japan,  and 
confirmed  in  consultations  with  Member  States  and  industry.  Clearly,  Member  States 
· acti~g independently cannot introduce this  measure. without a Community.  dim~nsion .as 
. such provision would be contradictory to Di~ective 65/65/EEC. Equally, if sucn  measures 
.  , were  adopted  m  an  uncoordinated· manner  by  the  Member  States,  this  would. create 
- 3 ~ obstacles to intra-Community trade, leading to distortions of  competition and run contrary 
-to a single market.. 
Since this proposaJ·concerns health, a high level ofhealth protection must be provided for, 
in  ~ccordance with Article 1  00a(3).  This means, in particular, that the market exclusivity 
granted to an· orphan medicinal  product when it  is authorised by the Community cim be 
withdrawn· if the criteria for designation are no· longer met or if the price charged ·for the 
medicinal product concerned is such that it allows the earning of an unreasonable profit . 
Moreover,  a second  authorisation may be granted  if the  holder of  the authorisation  is 
unable to supply a sufficient  quantity of the medicinal  product or if another medicinal 
pr()duct proves safer,  more effective or clinically superior to the one enjoying exclusive 
marketi'ng rights.  · 
Subsidiarity and proportionality 
As  pointed  out  in  the  Council  Resolution  of 20 December 1995  on  orphan  medicinal 
products (OJ C 350, 30.12.1995, p. 3), "a common European approach to rare diseases 
and orphan medicinal products holds out advantages in epidemiological, public health and 
economic terms". 
As  stated  above,  the  problem  of orphan  medicinal  products  has  to do  with  the  small 
number  of patients  concerned  and  the  low  commercial  interest  of the  medication 
developed to treat them.  A common and concerted Community approach is clearly mor'e 
likely to help solve this problem than isolated national initiatives.-
Furthermore, Community action allows the best possible use of the instruments set up in 
the pharmaceutical sector to complete the internal market, and in  particular the European 
Agency  for  the  Evaluation  of Medicinal  Products  and  the  Community  procedure  for 
authorising  the  marketing  of.  medicinal  products,  as  established  by  Regulation  (EEC) 
No 2309/93. .  · 
,/ 
Member States should not,  however, be prevented from  playing their part in  promoting 
research  and  development  work  on  orphan  medicinal  products.  ,  Accordingly,  this 
proposal provides for medicinal products designated. as orphan medicinal products to be . 
covered by the ~ommunity  procedure for the authorisation to place medicinal products on 
the market, but it does not rule out the use of  national procedures, particularly with regard. 
to mutual  recognition, ·where  these  are  considered  more  appropriate  by  the  operators 
concerned  .. Furthermore, the proposal invites the Member States to introduce incentives 
for· research and development work on orphan medicinal  products and for  placing such 
.  products on the market, within the framework oftheir own powers and respo_nsibilities. 
Legislative and administrative simplification 
The type of legislation proposed Is  a Regulation.  This instrument does: not have to be 
transposed into th_e Member States' national legislation and is well suited to introducing a 
Community  procedure  for  designating  orphan  medicinal  products  and  for  creating 
exclusive marketing rights.  · 
A  simple  and  swift  procedure is  laid  down  for  designating  orphan  medicinal  products, 
making  use  of the  existing  structures:  the  European  Agency  for  the  Evaluation. of 
Medicinal Products and the Standing Committee on Medicinal Products for Human Use·. 
.. i  !· 
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(whose opinion is;  however, required only where the Commission's ·proposal differs from 
the Agency's opinion).  ·  ·  · 
.  This. proposal for a  Regtilation ·establishes  the· general ,.legal framework.  Where  more 
detailed administrative provisions. are required, it. is proposed that they be adopted \:)y the 
Commission as guidelines,  in consultation with the Member States, the Agency and the 
parties concerned.· This is the normal way of  proceeding in the pharmaceuticaJ sector.  · 
Consistency with other Community policies 
The adcompanying  proposal  was  announced  in  the  Commission's  Communication  of. 
26 May 1997 concerning a Programme ofCommunity action on·rare diseases within the 
framework  Joraction in the field of  public health (COM(9~)225 final).  The main criterion 
for. des.ignating an  orphan medicinal  prod~ct within .  the meaning ·of  the  acc~mpanying 
proposal is  similar to the definition given as ·a  guide il1  the proposed Programme· fur the 
·concept of"rare diseases", i.e.  diseases with a prevalence In the Community population of 
less than5 per 10 000.  · 
\.  The  proposal  also  extends  the  wqrk  bei~g carried  out -under the Fourth Framewor_k. · 
Programme for Research and'Technologiccil Development (1994-199.8):  the Biomedicine 
. and Health Programme (Biomed 2) includes  a~ area entitled "Research.·on rare diseases"· 
which cov~rs resea:rch and development work on orphan medicinal products and supports 
. fundamental' and clinical research on rare diseases. 
Finally, this proposal follows ~p the Communication from the Commission on the outlines 
of an  industrial  policy for  the  pharmaceutical  sector  (COM(93}718  final).  -The 
. introduction  of incentives  for  R&D  work  on  orphan  medicinal  products  contributes 
towards the objective of support for  innov~tion .and towards the creation of a stable and 
foreseeable legislativ'e environment for pharmaceutical research in th~ European Union. 
Outside consultation 
.;  Interested parties have been widely consulted on this proposaL  In February 1995, a group 
of . experts · consisting  of_  civil  ser\rants,  · academics·  and  representatives  of  the 
pharmaceuticals industry and patients' associations met in Brussels to consider the results 
of a  study  which  had been  carried  out  for  the  Cohm1ission  and  to  draw from  it  the 
necessary conclusions. 
In Decemb~r 1995, the Council adopeted a. Resolution caJling .on the· Commission to  study 
the  situation  with  regard to orphan  medicinal  products  in  E~rope and  to 'make  any · 
appropriate proposafs for improving access to medicinal products intended, in  particular, 
for persons.sufferingfrom rare diseases,  -
In August 1996, Commission staff-distributed. to the interested. parties a ·preliminary draft ·· 
· proposal for  a  Regulat.ion  on orphan  medicinal  products.  This  was  discussed  at  two 
meetings of a working •  group of the Pharmaceutical Committee.  It ·was also· expounded . 
and discussed at a number of public meetings, notably within the context of  the. European. 
Parliament's Intergroup on Pharmaceutical Products.  / 
Following  these  consultations,  an  am~nded · preliminary  draft  was  prepared  '.in 
· December 1996.  This -.JleW  preliminary draft  received  wi~espread support; in  particular 
from  associations of  persons suffering  from ,  rare  diseases  ..  ·  Moreo~et, in  March 1997,-
- 5 -·these associations set up a European umbrella organisation (EuRORDIS), one of whose 
· m~in objectives· is  to  promote. the swift  adoption ·of  European legislation  on  orphan 
.  ~edicinal products.  · 
·  Evaluation· 
A number of  evaluation mechanisms are included in thi·s proposal. 
;Essentially, these mechanisms relate to the ten-year period of exclusive marketing 'rights, 
which provides the main  incentive for R&D work on orphan medicinal.  The exclusive 
marketing .rights constitute a particularly sensitive instrument which should be surrounded 
with appropriate safeguards.  That is why the proposal lays down that the exclusive rights 
may be withdrawn at the end· of  the sixth year at the request of  a Member State where the 
latter can establish that the conditions which origina!Jy Jed to the designation of  a product 
as an orphan medicinal product no longer apply. or that the price charged for the medicinal 
product concerned is such that it allows the earning of  an unreasonable profit.  Moreover, 
a  derogation may  be  granted  at  any  time  ei~her because  the  holder  of the  exclusive 
authorisation  cannot· supply  a  sufficient  quantity  of the  medicinal product or because 
another medicinal product has be.en shown to be safer, ·more effective or clinically superior 
to the product which has been enjoying exclusive rights.  -
The  proposal  also  provides that the  Commission  should  assess  _the  application  of the 
system  six  years .after it  had  been  introduced  and  sJ'tould,  within this  period,  publish  a 
report on the experience acquired.  ·  · 
· .  Impact on firms 
This proposal will  benefit>~]) firms engaged in  pharmaceutical research and development, 
regardless oftheir·size, location or sphere of  activity.  · 
It :·should,  however,  be noted that in  the United States- where a similar system to that 
being  proposed  has been  operating for  more than  12 years -·most applicatic!JS  for  the 
designation  _of.  orphan  medicinal  products  are.  filed.  by·  _small  fljJTIS  specialising  in 
biotechnology  and  genetic  engineering  (since  the  vast- majority  of rare  diseases  are 
developmental disorders of  a genetic or other kind).  · · 
No changes in  the industrial sector will result from the adoption of  this proposal, since it 
provides for an incentive· system which firms are clearly at liberty to ignore. 
. The  proposal  should  stimulate  pharmaceutical  research  and  development  within  th~ 
· .'Community, an_d  this can only nave· a  positiv~ effect in terms of  job creation ·(in particular 
highly-qualified jobs), i~vestment  and .the  creatio~ ofriew firms. 
There  is  no  particular.  provision  relating  to . small  and · medium-sized  enterprises.- . 
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PRESENTATION 
Scope 
.  '  ' 
The proposed system  covers medicinal  products for  human  use within  the  meaning  of 
Directive 65/65/EEC.  This includes  a~y substance or combination of substances which 
may be administered to human beings with a vi·ew  to making a medical diagnosis or for 
treating or preventing a disease. ·.It should be noted, in particular, that vaccines are thus 
covered.  ·  · 
This definition excludes medical deviCes and nutrition supplements.  This does not mean 
that these products· can· play  no role in  the. diagnosis,  prevention or- treatment of rare 
diseases.· However, the incentiv,e.arrangement introduced by this proposal can be;applied, 
by  means of  its own mechanism,  only to medicinal  products which- are covered by the 
marketing authorisation system.  · 
Medicines for veterinary use are also excluded, as will readily be understood from the aim 
·of the  proposal.  Although  a  similar  problem  arises  in·  the  field  of animal  health, 
particularly with regard to "minor species",  it  cannot be dealt with in the context of this 
proposal.  · 
Designation criteria 
It is generally accepted that two types of  criteria can be used for the designation of  orphan 
medicinal  products:  -~pidemiological criteria (the prevalence or incidence of the disease 
concerned within  a  given  population)  and  economic  criteria ·(the presumption that  the 
medicinal  product. ~o be  used  for  treating  the  disease  concerned  is  not  commercially 
viable).  These _two  types  of criteria  are  not  necessarily  mutually  exclusive  and  may 
therefore be combined.where appropriate.  ·  .I 
- .  .  .  .  .,  ' 
Epidemiological  criteri~ present  clear  advantages  as  they  are  much  better  suited  than 
--economic criteria to an objective evaluation at the time of c:Iesignation.  Assessing whether 
it  wiU  be possible to obtain a reasonable return on the ·investment needed to develop  a 
medicinal product many years before if is actually placed on 'the m~rket obviously involves 
· a good deal of  speculation. · 
In the United States, an economic criterion, was used initially (Orphan: Drug Act 1983):.  it 
had to be established that the costs of devdoping the ll}edicinal  product and supplying it 
to th.e  general  public  could  not  reasonably  be  expected 'to be  covered  by sales  of the 
medicinal product in  the United States.  This system,  however,  proved unsucce-ssful  and 
Congress ·amended·  it  in- 1984  by  adding  'a  concurrent . epidemiological  criterion: · . 
. designation may now be obtained by showing either that the condition in  question affects 
fewer than 200 000 persons or that the development costs cannot reasonably be expected 
to be covered.  All  designations obtained between -1984 and 1992 in  the United States 
-were awarde_d on the basis ofthe epidemiological criterion alone.  ·  · 
The only objection sometimes raised to th~ use of  epidemiological criteria is based on the 
obse~ation that some of  the medicinal products designated as orphandrugs in)he-United 
- 7-States have subsequently proved to be (extremely) profitable.  Such cases,  however,  are 
very rare (approximately 1% of  all designations!), which suggests that the epidemiological 
criterion  used  in  the  United  States  does  indeed  enable  appropriate  candidates  to  be 
selected for designation. 
It is  therefore proposed that an  epidemiological criterion,  based on prevalence,  be used· 
initially. In the above-mentioned Communicat}on concerning a programme of Community 
action  on  rare  diseases,  the Commission  has  proposed  to  define  rare  diseases  as  life-
threatening  or chronically  debilitating  diseases  which  are  of such  low  prevalence  that 
special combined efforts are 'needed to address them so as to prevent significant prenatal 
and ·early morbidity and. mortality 9r  _a  considerable reduction in an individual's quality of 
life or socio-economic potential; itis further indicated that, as a guide, low prevalence can 
be understood as meaning a prevalence in the total Community population of less than  5 
per  10 000. -For  the  sake  of consistency,  the  same  prevalence  is  proposed  in . the 
accomtianying proposal. It should be noted that this ratio  is  lower than that used in· the 
United States (7.5 per 10 000) and slightly greater than that used in Japan (4 per 10 000). 
Prevalence is  established within the Community so that medicinal  products  int~nded for 
preventing or treating diseases which  are very widespread in  the Third  World (tropical 
diseases, for example) but uncommon in Europe will benefit from the new system. 
It also  appears  desirable  to .  encourage  research  and  development  work  on  medicinaf 
products· for the diagnosis,  p_~evention or treatment of  certain conditions which, while not 
exactly fitting into the category of rare diseases,  have  hitherto  not benefited sufficiently 
from  medical  progress,  namely  life-threatening or chronically debilitating  communicable 
diseases.  These medicinal  products should  be awarded  the  status of orphan  medicin_al 
products even where prevalence of  the condition exceeds 5 per 1  0 000, always provided it 
can be shown that,  without the incentives provided by this status,  development of these 
medicimit products would not be undertaken.  · 
Finally, where it can be established that the marketing of an orphan medicinal product is 
proving more profitable than had been foreseen,  any Member State may request that the 
exclusive marketing rights be withdrawn at the end of  the sixth year following issue of  the 
authorisation to place the product on the market (see below "Market exclusivity").  , 
Committee for Orphan Medicinal Products 
With regard to the evaluation of  applications for designation,  it  seems reasonable in  the 
first  instance  to  use  the  existing  structures,  namely  the  European  Agency  for  th~ 
Evaluation ofMedicinal Products, set up under Regulation (EEC) No 2309/93, which has 
the necessary infrastructure and resources for carrying out tl)is task. 
The evaluation itself could,  no  doubt,  be  carried out by  the Committee for Proprietary 
Medicinal  Products - which,  within  the Agency, . is  responsible  for  all  scientific  matters 
relating to the evaluation of medici~al products for  human ·use.  This,  however, .  would 
present  a  number  of disadvantages.  For  one  thing,  it  would  confer  upon  one  single 
·Committee the power both to  express a view on applications for  designation as orphan 
medicinal product and, subsequently, to give opinions on applications for the authorisation 
to place  those  products  on  the  market.  Furthermore,  the  Committee  for  Proprietary 
Medicinal Products already has a considerable workload. 
-8-
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It  therefore  appears  preferable  to  establish  a  new  committee,  operating  within  ·the 
Agency - which would provide it with a Secretariat - and  consisting of persons appointed 
·by the Merriber States and selected on account of their role and experience in the field  of 
. rare·  diseases.  The  committee  would  also · have  three  representatives  of  patients' 
associations, to be designated by the  .Commission, and .three persons, also appointed by 
the. Commis·sion,  on a  recommendation from  the Agency,  specifically to liaise  with the 
Committee  for  Proprietary Medicinal  Products.  The  setting  up  of such  a  Committee,. 
·including  representatives ·of patients'  associations,  has  been  supported  both  by  the . 
Member  States'  representatives  and  in  the  context  of the  European  Parliament's 
Intergroup on Pharmaceutical-ProduCts. 
Designation procedure . 
.  .  .  -·  )  .  . 
The designation procedure should be flexible and rapid.  Applications would be processed 
by  the  Agency  Secretariat,  enabling  the Committee  for  Orphan  Medicinal  Products to 
deliver its opinion. within 60 days oft  he Secretariat's validation of  the application. 
The designation of an orphan medicinal product entails important legal consequences not 
only for. the sponsor but also .  for the third  parties concerned  and  must therefore be the 
subject  of a  decision·  by~ a  Community  institution,· in  this  case  the  Commission.  The. 
Comf!lission  would  nave  30  days  to.  take  this  ·decision.  Where,  in  exceptional 
circumstances, the Commission considers taking a decision which differs from the opinion 
·of the  Co~mittee for  Orpha_n  Medicinal  Products,  the  procedure  of the  Standing 
Committee  on ·Medicinal  Products  for  Human  Use  would . be·  applicable  (type  Ilia 
committee procedure). 
Protocol assistance 
.  .  - . 
. The development of an  orphan medicinal  product presents specific problems which must 
be taken into  ac.cou.nt.  To  take  put  one  example,  it  may  be  difficult  to find  enough 
patients willing to take part in  clinical  trials for  a medicinal  product which. might be of ' 
benefit only to a very few people .. · 
The  proposal  therefore  allows  the  sponsor  the  possibility  of requesting  the  Agency's 
assistance in  developing a protocol, in  carrying out or following  up  clinicar trials and.in 
connection with any o!her matter relating to the application for an authorisation. 
Community marketin·g authorisation 
The Community marketing authorisation (issued by the Community under what is kqown · 
. as. the "centralised  procedure")  is  the  simplest  ,and  quickest .  way  of placing  medicinal 
product  on the  market  throughout  the  Community.  Orphan  medicinal  products  must 
·therefore be given (easier) access to this procedure.  Two measures are provided for this 
purpose. 
First, the applicant for an authorisation relating to an orphan medicinal product should. be 
exempted from the requirement to show that the medicinal-product meets the conditions 
·set  out in  .the  Annex  to  Regulation  (EEC)  No 2309/93.  In  most  cases,  an  orphan 
medicinal product will indeed meef the. criteria set out in that. Annex, either because it has 
been  produced by  biotechnology  (most  rare  diseases .are  developmental  disorders of a 
.  I  .  '  ' 
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I. genetic or other kind  and the diagnosis, prevention or treatment of  such diseases normally 
calls for  gene~ic engineering),  or because the medicinal  product is  regarded as being of 
significant therapeutic importance.  The simplest solution, however, is to lay down that an 
orphan medicinal product has full right of  access to the centralised procedure. 
·secondly, it  must be borne in  mind that access to the centralised procedure is subject to 
the payment of a fee to the Agency; in accordance with Regulation (EEC) No 297/95.  In 
the case of a medicinal  product whose commercial viability  is  doubtful,  the payment of 
this fee  may constitute a serious obstaCle.  Moreover, people suffering f~om rare diseases  . 
11ave  the right to expect the same guarantees of quality,  safety and  efficiency as  for any 
other medicinal product, and there should be no question of lowering these standards. A 
mechanism  must therefore be  set  up  whereby the applicant  for  an  authorisation· for  ~m­
orphan medicinal  product could be exempt from  paying  all  or part of  the fee  while the 
Agency (and thus the rapporteur and expe_!ts responsible for the evaluation) would be paid 
for the services provided. Accordingly, it is proposed to introduce an annual contribution, 
-from the Community budget, to be allocated specifically to exemptions from  fees  in  the  -
case of  orphan medicinal products (see the Financial Statement). 
It should be noted that, while the centralised procedure can certainly be used for orphan 
medicinal  produ~ts, such use is not obligatory. Any such obligation would be incompatible 
with the aim  of this proposal and with the principle of proportionality.  If,  for whatever 
reason,  the  sponsor  of ah  orphan  medicinal  product  prefers  to use  the  decentralised 
procedure (mut_ual recognition), he must be able to do so. 
Market exclusivity 
Market exclusivity  is  unanimously  regarded  as  crucial  to  any  system  of incentives  for 
research and development work on orphan medicinal products. 
In  the accompanying  proposal,  market exclusivity  is  granted  only' where the medicinal 
product has been designated as an orphan medicinal product by the CommunitY and where 
the Community has issued a marketing authorisation in  respect of the medicinal product 
conce.med. 
The · protection  thus  ·granted  prevents  ~he  Community  or  a  Member  State  from 
subsequently Issuing a marketing authorisation for the same product(, i.e. the same active 
substance)  and  for  the same  indication-_  It does  not  prevent  the ,marketing of another 
product  for  the  same  indication,  which  would  constitute  an _unjustified  restriction  on 
therapeutic innovation,  on the rights of third  parties and  on patient expectations.  It is 
certainly  not  easy  to  establish  the  degree  of similarity  between  medicinal  products, 
particularly in  the case of macro-molecules (proteins) which  differ  only  very  slightly in 
their sequence ofamino-acids:  Experience acquired in  the United  States in this field  will 
be particularly useful  in  helping the Commission to draw up  the necessary guidelines,  in 
consultation with the Member States and the Agency. 
It is important to note that designation alone confers neither exclusive rights nor rights of 
precedence. It follows that a number of sponsors may,  in _principie,  obtain the designation 
of  the same product/indication combination, subject to the application of' other intellectual 
property nghts which, of  course, are in rio way aff~cted.  In this event, the fi-rst  sponsor fo 
obtain a Community marketing 'authorisation for this product/indication combination will 
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prevent  the  other, sponsor(s)  from  subsequently  obtaining  a  Community  or  national 
authorisation for the same product/indication combination. 
It is proposed to limit the duration of  the excl~sive right within the Community to a period 
of tenyears· (seven years in the United States).  l(hi~ is  th~ same _period  as is 'granted for, 
the protection of data relating to the test results provided by the holder of the marketing 
authorisation in  support of his ·application.'  This period may,  however, be reduced to six 
years at the request of a Member State if the latter can show either that -the  criterion or 
cryteria ,used  at  the time of designation  no longer apply  (prevalence of less  than 5  per 
10 000. or ·presumed commercial non-viability  of a  medicinal: product  to  be  used  for 
treating a  life-threatening or chronically  debilitating  communicable  disease) ·or  that the 
holder ofthe marketing authorisation demands a price for the product which cannot be 
justified.  ,  ·  . 
.  .  .  \  . 
Although. market· exclusivity ·is  very  important  in .  encouraging industrial  firms  to  spend 
money on research which  is  of low  commercial  interest,  it  must not be  allowed to run 
counter': to the interests of  patients or  the requirements of public health.  Accordingly, this 
'proposal  provides for  a  possible  derogation from' the exclusive  marketing  rights  if the  . 
holder of  those rights is unable to' provide the medicinal product in sufficient quantities or 
if another applicant can show that ·his own version of the medicinal  product is  safer or 
more effectiv·e.  The~e matters will ·also be. dealt with in the above-mentioned guideJines to 
be published  by the Commission.  It should  be  noted that where  such  a -derogation  is 
granted;  the .market  exclusivity  is  not  ~ctually .withdrawn,  and  still  prevents  further 
authorisations, for the same medicinal product. in the same ·indication. 
.  .  ~· 
Other incentives 
.·  .  . 
Market  exclu~ivity is  undoubtedly· the· primary  incentive for a· firm  to develop  orphan 
medicin~l products, but it is certainly not the only one.  It would be up to the Community 
and the: Member States, within their respective spheres' ofcompetence, tp  provide other 
incentives  .  for  d~veloping. fDedicinal  .·  products. - notably,  but  not  exclusively,  those 
designated  ~s orphan medicinal  products by  the Community.  At Community level,  the 
main incentives will rio, doubt take the form of  support for research.  At nationallevel, tax 
incentives (in particular tax cre~ts) will provide the most effective stimulus fo research. 
The Commission will draw up a  detail~d list of  all the incentives available, on the basis of 
information provided by the. Member States. 
~  ,.  . 
- 11  -TEXT OF THE PROPOSAL 
Pro'posal for a European  ·Parliament and Council 
Regulation (EC) on orphan medicin.al products 
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROI>EAN UNION; _ 
Having  regard· to the  Treaty establishing  the  European  Community,  and  in  particular 
. Article -IOOa thereof, .  . 
Having regard to the proposal from the Commissiofl, 
- . 
Having regard to the opinion·ofthe Economic and Social Committee, 
.  ~ 
Acting in  accord~ricewlth the procedure laid down in ·Article 189b of  the EC Treaty, 
(I). Whereas  some  conditions  occur  so  infrequently  that· the  cost  of developing  and 
bringing to the market a .medicinal·produci to'diagnose, prevent or  _treat the condition 
would not be recovered. by the expected sales of  the medicinal product ; whereas the 
pharmaceutical industry would be unwilling to· develop the medicinal  product under· 
normal  market  conditions ; .  whereas .  these  medicin'a~ .  products  are  therefore  called 
" orphan " ; · 
(2)  Whereas patients suffering fro~ rare diseases should be entitled to the same quality.of. 
treatment  as  other  patients ; .  whereas  it  is  therefore  necessary  to  stimulate  the . 
research, development and bringing to the market of appropriate. medications by the 
pharmaceutical industry ; whereas incentives for the development oforphan medicinal  . 
products ·have  been  available  in  the  United· States  since  1983 _and  in  Japan. since 
!'993;.  . 
(3). Whereas, in· the European Union,, only limited action has beeri taken so far, whether at  . 
national  or at  Cotnmuniiy  level,  to stimulate the developmertt of orphan medicinal 
products ; whereas  such  action is  best taken at  Community level  in  order to take 
advantage  of the  widest  possible  market  and  to  avoid  the  dispers.ion  of limited 
resources ;  whereas  action  at  .  Community  level  is  _preferable  to  uncoordinated 
measures by  the Member States which  may  resuit in  distortions of  competition and 
barrieJ."s to-intra-Community trade;  ·  ··  · 
.,  . 
(4)·  Whereas  orphan  medicinal  products  eligible  for· incentives  should  be  easily  and 
unequivocally  identified ; whereas it  seems  most  appropriate  to  achieve  this  result 
through the establishment of an  open and  transparent Community proce.dure for the 
designation of potential medicinal products as orphan medicinal products ; 
(5)  Whereas  objective  criteria  for  designation  should  be  established ;  whereas  these 
criteria should  be  based  on the  prevalence  of the  condition  for  which  diagnosis, 
prevention  or treatment  is  sought;  whereas  a  prevalence  of no  more  than  five . 
.  affected person per  ten thousand •  is generally regarded as the appropriate threshold ; 
-whereas· medicinal  product  intended  for  a  life-threatening  or seriously  debilitating 
communicable disease should be eligible even wheri the prevalence is higher than five 
per ten thousand ; 
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6)  Whereas a  Committee composed· of experts  appointed  by  the Member· States  by 
reason of their experience in  the research or treatment of such conditi'ons should be 
established to examine applic;;ttions for  designation ; whereas this Committee should 
in addition include three representatives of patients' associations, to be  designated by 
the Commission,  and three other persons,  also designated by the Commission,  on a -
. recommendation from the Agency ; whereas the Agency should be responsible for the 
· adequate co-ordination between the Committee on orphan medicinal products an·d the 
Committee on proprietary medicinal products ; 
(7) Whereas patients with such c<:mditions deserve the same quality, safety and efficacy in 
medicinal  products  as  other  patients ;  whereas  orphan  medicinal  products· should 
therefore be submitted to the normal evaluation process ; V\lhereas  spon~ors of orphan 
medicinal  products- ·should  hcwe . the  possibility  of  obtaining  a  Community 
authorisation;  whereas,  in  order . to  facilitate  the  granting  of ·a  Community· 
authorisation,  the fee  to be  paid·  to the Agency should· be  waived  at  least  in  part ; 
whereas  the  Community  budget  should  compensate  the  Agency  for  the  loss  in . · 
(8) 
(9) 
rev~nue·thus occurred; .  · 
Whereas experience in the· United  Stat~s and Japan shows that the strongest incentive 
for· industry to invest iri the development and marketing of  orphan medicinal p'roducts 
is  the  prospect~of obtaining market exclusivity for a certain number of years during  . 
wh~ch part of the  investment 'might  be  recovered ; . whereas  data  protection. under -
article  4(8)(a)(iii)  of Council  Directive  65/65  is  not  sufficient ,incentive  for  that 
purpose;  whereas ~market exclusivity should. however be  limited  to  the therapeutic 
indication  for  which  orphan  medicinal  product" designation  has  been  obtained ; 
whereas,, in  the  interest  of patients,  the  market  exclusivity  granted  to  an  orphan 
medicinal product ·should  not prevent the marketing of a similar medicinal  which is 
safer, more effective or otherwise clinically  superio~  ~  .  · 
Whereas· sponsors of orphan  medicinal. products .designated  under this  Regulation 
should be entitl~d to the full benefit of  any incentives granted by the Community or by 
the Member States to support the research and  development of medicinal  products 
for the diagnosis, prev·ention or treatment of such conditions, including rare diseases ; 
• (1 0) Whereas the specific programme Biomed 2,  of the Fourth Framework Programme 
for research and  technological development ( 1994-1998);  is  supporting research on 
the treatment 'of rare  diseases,  including  methodologies  for  rapid  schemes  for  the 
development  of orphan  medicinal  products  and  inventories  of available  orphan _  _. 
medicinal in. Europe; whereas these grants are to promote the establishment ofcross 
national · co-operation  in  order·· to· implement  basic  and  clinical  research  on  rare 
diseases;  whereas  research  on  rare  diseases  will  continue  to. be  apriority for. the. 
Commission, as  it  has  been  introduced  in  the  Commission's ·proposal for  the Fifth 
Framework Programme ·(1998:..2002)  for  research,and  technological  development  ; 
whereas this Regulation.establishes a legal framework which will  allow. the swift and 
effective implementation of  the outcome of  this research,; 
I· (ll)Whereas rare diseases have been identified as a priority area for Community action 
within the framework for action in  the field  ofpublic health (COM(93) 559-final); 
whereas  the  Commission;  iri  its  communication  concerning  a  programme  of 
Community action on. rare diseases within the framework for action in the field  of 
public health (COM(97) 225  final)  has decided to give rare diseases priority within 
the  public  health ·framework ; whereas the Commission  has  proposed  a  European 
· Parliament and Council Decision adopting a prograinme of Community action 1999-
2003 o.n rare diseases in the context of  the framework for action in the field of  public, 
including actions to provide information,  to deal  with clusters of rare diseases in  a 
population and .to support  relevant  patient  organisations;  whereas this  Regulation 
carries out one ofthe priorities laid down in this programme of  action, 
HAVE ADOPTED THIS REGULATION : 
·, 
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Article I 
Purp.ose 
The purpose.of this Regulation is to lay down a Community procedure for the designation 
of medicinal  products as .  orphan  medi,cinal  products and  to provide  incentives  for  the 
r~search,  development  and  bringing  to  the . inarket  of designated  orphan  medicinal 
products. 
Article 2 
Scope and definition"s 
For the purpose of  this Regulation : 
. - medicinal product means a medicinal product for human use, as defined in Article 2 of 
Directive '65/65/EEC; 
- orphan medicinal product means a medicinal product designated under the terms and 
conditions of  this Regulation, 
.\pon.wr means any legal  or natural  person, established in the Community,  seeking to 
. obtain the designation of a  medicinal product as orphan me.dicinal product,· 
- Agency means th~ European Agency for the Evaluation of  Medicinal Products. 
Article 3 
Criteria_for designation 
.  -.  1.  A-medicinal product  shall be designated as orphan medicinal product if  its sponsor can 
establish that  the  medicinal  product  is  intended  for  the  diagnosis,  prevention  or 
· _ treatment  of a  condition  affecting. less  thim- five  per  ten  thousand  persons  in  the 
. Community· at  the  time  that. the  application  is  made ·.and · that  there  exists· no 
satisfactory method of diagnosis, prevention or treatment of  the considered condition 
that  has  been  authorised  in  the  Community  or,  if such  method  exists,  that  it  can 
reasonably be expected that. the -medicinal  product  will  be safer, more effective  or 
otherwise clinically superior. 
· 2.  Notwithstanding·paragraph 1,  a  medicinal  product may also be designated as  orphan 
medicinal produ~t ifits sponsor can establish. that th~  ·medicinal product is intended for 
a life.;.threatening or seriously debilitating communicable disease in the Community-and· 
. thatit is unlikely that, without incentives, the marketing of  the medicinal-product in the 
community would generate sufficient return to justify the necessary-investment. 
3.  The  Commission  shall,  in  consultation  with  the  Member  States,  the  Agency  and 
interested parties, draw up detailed g"!idance for the application ofthis-Article: 
- 15 -.. Article 4 
Committee for Orphan Medicinal Products 
1.  A  Committee  for  Orphan · Medicinal  Products,  hereinafter . referred  to  as  'the 
Committee', is hereby set tip.  .· 
2.  The task of  the Committee shan be.: 
a)  to .examine  any  applic~tion for  designation of a  medicinal product. as  orphan 
· medicinal product which is submitted to it in accordance with this Regulation, 
b)  upon request, to advise the ~ommission on the ,establishment and development of 
an orphan medicinal product policy for the European Union, 
c)  to assist  the  Commission  in  international  liaison  on  matters  relating  to  orphan · 
medicinal products, particuhJ.rly the United States and Japan, and in  liaisons with 
patients support:groups. 
3.  The Committee_ shan  con~ist of one member nominated by each Mem9er State, three 
members nominated by the  Commission to represent patient organisations and three 
.  members nominated by  the  Com~ission on the basis of a recommendation from the 
. Agency. The members of the Committee. shall  be appointed ,for a term of three years 
which shall be renewable. They shan be chosen by reason of  their role and experience 
in treatment of  or research into rare diseases: 
4.  The Committee shall elect its Chairman for a term of  three years, renewable once. 
5.  The representatives of the  Commission· and  the  Executive  Director of the  Agency 
Agency or his representative may attend ail meetings of  the Committee.· 
6.  The Agency shall provide the Secretariat of  the Committee. 
Article 5 
Procedure for designation 
1.  In order to obtain the designation of  a medicinal product as orphan medicinal product, 
the sponsqr shall submit an application to the Agency.  · 
2.  The application shall be accompanied by the following particulars and documents: 
a)  name or corporate name and permanent address ofthe sponsor, 
b)  qualitative and quantitative particulars of  the medicinal product, 
c)  proposed therapeutic indication,· 
d). the  j~stification  th~t Article 3 paragraph. 1 ~r  '2 is applicable. 
3.  The  Commission  shall,  in  consultation  with  the  Member  States,  the  Agency  and 
interested  parties,  draw  up  detailed. guidance  on  the  format  and  content  in  which 
appiicat~ons for designation are tp be presented.  . 
4.  The Agency shall verify the validity of  the application and prepare a summary report to 
the  Committee.  Where  appropriate,  it  may  request  the  sponsor  to  supplement  the 
particulars and documents accompanyi!lg the application. 
5.  The Ag~ncy shall ensure that an  opinion is· given by  the Committee within 6.0  days of 
the receipt of  a valid application.  ·  · 
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6.  When preparing its opinion,  the  Committee shall  use its best endeavours to reach a 
conseJ;lsus.  If such  a  consensus  cannot  be  reached,  the  opinion  shall  consist of the 
position  of the  majority  of members.,  The  opinion  may · be  obtained  by  writteri 
procedure.  · 
7.  Where the opinion of  the Committee is that the application does not satisfy the criteria . 
set ouf in Article 3 paragraph 1, the Agency shall forthwith inform the sponsor. Within 
· 30 'days of  rec~ipt of  the opinion, the sponsor may submit detailed grounds for appeal, . 
which the Agency shall refer to the Committee. The Committee shall consider whether 
its opinion sho'uld be revised at the following meeting  . 
8.  The  Agency  shall  forthwith  foi!Vard  the  final  opinion  of the  Committee  to  the 
Commission,  ~hich shall  adopt a  decision  within  30 days of receipt of the opinion. 
Where, excepti9nally, the draft decision is  not in  accordance with the opinion of the 
Committee, the decision shall be adopted in  accordance with ·the procedure laid down 
in  Article 72 ·of Regulation (EEC) N° 2309/93.  The decision shall be notified to the 
sponsor imd  communicated to the  Agency  and  to  the competent  authorities of the 
Member States. 
· 9.  The  designated  medicinal  product· shall  be  entered .  m  the  Community  Register.· of  . 
Orphcm Medicinal Products.  · 
Artir;le. 6 
Protocol assistance · 
1.  The.· sponsor  of an  orphan  medicinal  product  may,  prior  to  the  submission  of an 
application  for  marketing  authorisation,  request  advice  from  the  Agency  on  the ·· 
conduct of  the various tests and trials necessary to demonstrate the quality, safety and  ·: 
efficacy ofthe medicinal product.  ·  · 
'  -....._  . 
2.  The  Agency  shall  draw  up'  a  procedure  on the  development  of orphan  medicinal 
products, which shall cover in particular': 0 
a) assistance  in  the  development .of a· protocol  and.  for  the  follow  up  of clinical 
investigations, 
b) regulatory, assistance  for  the  definition  of the  content  of the  application  for 
. / authorisation  within  the  meaning  of Article  6  of Council  Regulation  (EEC)  N° 
2309/93. 
Article 7 
Community marketin~ authorisation  · 
1.  The person responsible for  placing on the· r:narket  an  orphan  medicinal  product may 
request that authorisation to place the medicinal  product on the market be granted by 
the Community in  acc.ordance with the provisions of Regulation (EEC) N°  2309/93 
without having to justify that the medicinal  product qualifies  under any  part of the 
Annex to that Regulation.  ' 
2.  A special. contribution from the Community, distinct from that provided for  i~ Article · 
57 of  Regulation (EEC) N° 2309/93, will be allocated every year-to. the Agency.  This 
contribution will  be used exclusively by the Agency to waive,  in  part or in  total,, the 
fees  payable  under  Community  rules  adopted  pursuant  to_  ~egulation  (EEC) ·-N° 
':' 17-2309/93.  A  detailed  report  of the  use  made  of this  special  contribution  shall  be 
presented by the Executive Director of  the Agency at the end of  each year. Any surplus 
occurring  in  a  given _year  shall  be carried  forward  and  deducted- from  the  special 
contribution for the following year. 
3.  The marketing authorisation granted for an orphan medicinal product shall cover only 
those therapeutic indications which fulfil the criteria set out in article 3.  This is without 
prejudice to 'the  possibility to apply for a  separate marketing authorisation for other 
indications outside the scope of  this Regulatio~. 
Article 8 
Market exclusivity 
1.  Where a marketing authorisation is granted pursuant to Regulation (EEC) 2309/93 in 
respect of an orphan medicinal  product, the Community and the Member States shall 
not, for a period of  ten years, accept another application for a marketing authorisation, 
nor grant a marketing authorisation or extend an existing marketing authorisation, for 
·the same therapeutic indication, in respect of  a similar medicinal product. 
2.  This period  inay  however be reduced  to six  years  if,  at the end of the fifth  year,  a 
Member State can establish that the criteria laid down in Article 3 are no longer met in 
respect of  the medicinal product concerned or that the price charged for the medicinal 
product concerned is  such that it a1lows the earning of an unreasonable profit. To this 
end, the Member State shall initiate the procedure laid down in Article 5 .. 
3.  By derogation to paragraph I, and without prejudice to intellectual property Jaw or any 
other provision of Community Jaw,  a marketing authorisation may be granted, for the 
· same therapeutic indication, to a similar medicinal product if: · 
.  a)  the holder of the marketing authorisation of  the original orphan medicinal product 
·has· giveri his consent to the second apJ?Iicant, or  · 
b) the holder of  the marketing authorisation of  the original orphan medicinal product is 
unable to supply sufficient quantities ofthe medicinal product, or 
c) the  second  applicant  can _establish  in  the  application  that  the  second  medicinal 
product,  although  similar  to  the  orphan  medicinal  pr_oduct  already  authorised,  is 
safe~, more effective or otherwise clinically-superior. 
4.  At the end of the period of market exclusivity, the orphan medicinal product shall  be 
remove4 from the Community Register ofOrphan Medicinal. 
5.  For the purpose of  this Article,- a 
11Similar medicinal product" means one which consists 
of: 
the same. chemical  active  substance or active  moiety of the. substance,  including 
isomers and mixture of isomers,  complexes, esters, other non-covalent derivatives, 
provided  that  the  pharmacological  and  toxicological  activities  of the  latter  are  , 
qualitatively and quantitatively identical to those of  the original product, 
a substance with the same biologidll  activity (including those that differ from  the 
original \Substance  in  molecular  structure,  source  material  and/or  manufacturing 
process) provided t~at the pharmacological activity ofsaid substance is qualitatively 
and·quantitatively ide!'~ical to that ofthe original product, 
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- a  substance  with  the  same  radiopharmaceutical  activity  (including  those  with  a 
different  radio nuclide,  ligand,  site  of labelling  or  molecule~radionuclide coupling· 
'mechanism) provided that its diagnostic or therapeutic indications are identical to 
.. ·those of  the original product. 
· 6.  The  Commission  shall,  in  consultation  with  the  Member  States,  the  Agency  and. 
interested parties,  draw up detailed guidance for the applic~tion of  this Article. 
Article 9 
Other incentives · 
1.  Medicinal .products designated as orphan medicinal  pr~d~cts under the provisions of 
this Regulation shall  b~  elig~ble for incentives made available by the Community and by 
the Member States t0 support the.  research,  development  and availability  of orphan 
medicinal products.  ·  · 
2.  Within  six  months. of the  adoption  of this  Regulation,  the  Member.  States  shall 
communicate to the  Commission  detailed  ihfonriation  about the measures they have 
enacted  to  support· the  research,  development  and  availability  of orphan  medicinal 
products. Thi_s information shall b.e  updat~d on a regular basis . 
. l. Member States shall  also  consider  wai~ing, in  part or in  total,  the fees to be paid in 
respect of  applications to place orphan medicinal .products o~  the market. 
4:  Within one year from  the .adoption of this Regulation, the Commission shall  publish  a_ 
·  detailed inventory of all  incentives made available by the Community and the Member 
States  to  support  the' research,  development  and  availability  of orphan  medicinal· 
products. This inventory will. be updated on a regular basis. 
(  . 
Article 10 
G~~eral  ~~eport 
Within six years of  the entry into force of  this Regulation, the Commission shall publish a 
general report on the experience acquired as a resultofthe application of  this Regulation. 
Article 11  · 
Entry into force 
This Regulation shall. enter into force on the thirtieth day following its puglication in the 
··  OfficialJo.urnalofthe European Communities.  ·  · 
.  / 
This  Regulation  shall be binding  in  its  entirety and ·  directly  applicable  in  all  Member  ; 
States.  ·.  · 
. ·-19-FINANCIAL STATEMENT 
1.  TITLE OF OPERATION , 
Proposal for a European Parliament and Council Regulation on orphan medicinal 
products 
2.  BUDGET HEADING INVOLVED 
85-3120 
85-3121 
3.  LEGAL BASIS 
CommunitY Contributiori·to EMEA budget  - EMEA staff  and operational·  '  . 
expendi~re related  to the  functionning  of the  Committee  for· Orphan  . 
Medicinal Products and the provision of  protocol assistance. 
Special contribution for orphan medicinal  products for the financing· 9f 
fcc exemptions (to be created)  . 
Art  IOOa of  the Treaty establishing the European Community 
4.  DESCRIPTION OF OPERATION. 
4.1  General objective 
The_prescnt proposal aims at: 
•  establishing a Community procedure for the designation of  orphan medicinal products 
•  setting out incentives  for  research, development and  marketing of orphan  medicinal 
products; in particular by the granting of  a  I 0 year market exclusivity period. 
4.2  Period covered  and arrangements for renewal 
The proposed Regulation has no fixed duration. 
The Commission will publish, within one year from entry into force of the Regulation,  a 
detailed inventory of all  incentives made available by Community anp Member States to 
support'the research, development and availability of  orphan medicinal products, 
The  Coriunissi~n will publish within 6 years of  entry into force Qf the. Regulation ·a general 
report op experience acquired.  ·  ·  ·  ·  · 
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5.  CLASSIFICATION OF EXPENDITUR~  OR REVEN'UE~ 
NCE;NDA 
.  6~  ·  TYPE OF EXPENDITURE. OR REVENUE 
Contributions from the Community will cover the following types of  expenditure: 
6.1  · EMEA  operational  expenditure  related  to  the  designation  of. orphan  medicinal 
products . (Title  3  of  EMEA  budget),  Compensated  by  the  basic  Community 
~ontribution to the EMEA budget. · , . 
· 6.2  '.''EMEA  staff expenditure  related to designation  and protocol  assistance for  orphan 
medicinal products (Title 1 of EMEA budget), compensated by the basic CommunitY 
contribution to the EMEA budget. 
6.3  . Fee exemptions for applications for protocol assistance and marketing authorisations 
.  (Title· 3' of EMEA budget),  compensated by. the special  Community contribution to 
.  the EMEA budget for medicinal products.  ·  · 
7.  FINANCIAL IMPACT 
The  management  of  applications  for  designation,  protocol  assistance  an<i  marketing 
authorisations will result in thefollowing expenditure on the EMEA budget. 
Meetings costs  at the  EMEA and  staff costs to be financed  by the basic  s~bsidy.  Fee 
exemptions will be fiminced by a a special contribution from the Community budget. 
•  •  •  I 
.  Projections are based on the following estimated number of applications for designation and 
fee  waivers for  protocol  assistance  and  marketing  authorisations  under  the  centralised 
proeedure : · 
Projected ·number · of applications -for  designation,  protocol  assistance  and  marketing. 
authoriSC;ltions for orphan medicinal products :· 
•  c \  l  I 
, 
I 
Year  2000  2001  20()2  2003 
Number  5  8  12  12 
.,  ....... 
-21 ~ 
I' 7.1  Meetings  costs  and staff costs  to  be financed  by an increase of EMEA basic 
subsidy  · 
/  A - Meetang costs 
Quarterly tWo-days  meeti~gs of  the Committee for Orphan Medicinal Products at · 
the EMEA with interpretation.  · 
Reimbursement  of travel  and  accommodation  expenses  for  21  delegates  in 
accordance with the rules set out by the Management Board of  the Agency. 
Cost per meeting (ECU) in 1998  24 000 
' 
Total annual meeting costs (4 meetings per year)  96 000 
2000  2001  2002  2003 
100 000  102 000  104 000  106 000 
· B - EMEA Staff costs 
The  management  of designation  and  protocol  assistance  for  orphan  medicinal 
products will require the creation· of  a specific team within the EMEA Secretariat. 
Team human resources and corresponding staff costs (in ECU at current costs) 
Annual saBary  Total team  Total team 
Position and grade  per staff  direct staff  staff costs 
member  costs  (including· 
overheads) 
I principal administrators (AS)  94 000  94 000  l24 080 
3 scientific administrators (A 7)  70000  210 000  277 200 
" 
1 administrative· assistants (B3)  56000  56 000  73 920' 
' 
2 clerical assistan~ (C3)  45 000  9o o"oo 
.·· 
118 800 
-
Total staff costs per budget year  450 000  594 000  . 
C - Total of  meet~ng and staff costs 
2000  2001  ~2002  2003. 
Meetings  100 000  102 000  104 000  106 oob 
Staff  400 000  . 606 000  618 000  630 000 
' 
TOTAL  500 000  708 000  '722000  736 000 
~, 
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7.2 
-
Fee exemptions to be fin~nced by a special Community contribution to. EMEA · 
Under  article 7(5) of Council  Regulation  (EC)  297/95  on  fees  payable  to  the 
EMEA, the Executive Director may grant fee waivers or reductions to-applications 
.submitted under- d1e  centralised procedure,  in  exceptional  circumstances and for· 
imperative reasons of pub1ic and animal health.  Fcc exemptions arc granted after 
consultation ·of the'  competent  scicntifid  committee  on  the  basis  of criteria 
determined by the Management Board.  . 
The  same  procedure  would  be  used  for  fee  exemptions  or  reductions  for  . 
applications for marketing authorisations for orphan medicinal products under the 
hew Regulation.  r  -
On the basis of  the  curr~nt proposal for a Council Regulation on fees  payable to -
the EMEA; the basic fee for a full application for a marketing authorisation would 
amount to ECU 200 '000.  The contribution for fee  exemptions  is  based on the 
expec~d number 'of applications. and  on  the. assumption that,  on  average;  fees 
would be reduced by half.  . 
7.3 Overall budgetary impact 
The •  overall  impact  of the  proposed  measures  on  the  EMEA budget  can  be 
. estimate<l as follows and would determine the basis for Community contributions . 
.  ; 
Contributio~s would be constituted by the following : 
- -
2000  2001  . '2002  . 2003. 
.. 
Community contribution .  -·  ··.  736 000  500 000  708 000  722 000 
(meeting  and staff costs)  -· 
/ 
Special Community  500 000  .800 000  1 200 000  1 200 000 
contribution for fee 
exemptions  . 
Total  1'000 000  1S08 000  1 922 000  1936 000 
8.  FRAUD PREVENTION MEASURE 
.  ' 
Council  Regulation • (EEC)  No  2309/93  provides  for  specific·· adoption  and .. 
budgetary  control . procedures.  The  . Management  Board,·  composed . of 
representatives of  Member States, Parliament and Commission, is responsible for 
.  adoptin~ the annual draft budget (Article 55)  .. Budgetary control mechanisms are. 
·described in Article 57, inCluding the appointment of a financial controller by the 
Mana~ement  Board.  · 
-23.; 9.  ELEMENTS OF COST  -EfFECTIVENESS ANALYSIS 
' 
·9.1  Specific and quantitative objectives 
In  its  R~solution of 20  December  1995  o~ orp~  drugs (OJ no C  3SO,  30.12.1995), 
. Council ~lled for ..  a.common European approach to rare diseases and orphan ·drugs" with a 
view to hold "advantages in epidemiological,·public health and economic terms" and called 
on  the Commission to ."make appropriate proposals 'with a  view to improving  ~ccess to-
medicinal_produ~s  intend~  particularly for people suffering from rare d_iseases". 
This  proposal  is  designed. to  harmonise  the  legislative  provisions  relating  to  orphan 
_· medicinal products and creates incentives for the research and development at Community 
level, without prejudice t~ other incentives which co~ld  made available ~t national level. 
.  .  . 
The proposed Regulation Will in particular allow for access to EMEA resources to sponso~s, 
and in particular :  .  ' 
Scientific rcsa'urccs made available-by Member States to the EMEA for evaluation work, 
notabiy  the  network of 2  000  experts  covering  the  full  range of expertise needed  to 
ensure the highest possible quality of  the Agency's scientific opinions. 
- Direct access to the centralised procedure which  allows  for a speedy and high  quality 
- review leading to· tfie granting of a single authorisation to rriarkct valid throughout the 
·community; thereby ensuring quick availability pf  medicinal products to patients whilst 
allowing sponsors a speedy.return on investments.  · 
In addition, the Regulation provides for financial and technical ~sistance as follows 
- Following  designation;  possibilitY -of fee  exemptions  for  applications  for  marketing 
authorisations  and  scientific  and  regulatory  advice,  'Yhich  will  facilitate  access  to 
centralised procedure in particular to small and medium size enterprises ; 
.  - .  '  .  I 
- ·.  Scientific/regulatory advice and protocol  assistance, which  will  provide sponsors with 
the scientific and regulatory expertise available at EMEA, in  particular in the follow up 
. of  clinical trials and preparation of the dossier. The close involvement of CPMP and its 
working  parties  in  the  process  will  establish  a  link  which woulcl  eventually  facilitate 
evalua~ion pf  the dossier should the sponsor choose to submit the application under the 
centralised procedure.  · 
9j Grounds for the operation 
'  . 
The Regulation provides for efficient mechanisms .and substantial incentives for research 
and  dev~lopment likely to  facilitate access to European patients of medicinal  products 
intended for rare ~isea.Ses, in line with Commun~~y  policy in this ,respect. 
·  9.3  Monitoring and evaluation of the operation 
A  detailt<d  report  of the. use  made  of the  Community's  special  contribution  will.be 
presented by the Agency's Executive Director at the end of  each year.  , 
·In  addition,  time  for  designation  of orphan  medicinal  products,  time  to  marketing 
authorisation and availability of orphan medicinal products on the European market will 
be assessed,  particularly in comparison with the USA and Japan, as part of  the EMEA's 
performance goals and targets monitored by the EMEA Management Board. 
------------------------------------------------ .  .  . 
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